203 related articles for article (PubMed ID: 36243853)
1. PI3K Isoform Immunotherapy for Solid Tumours.
Scott J; Rees L; Gallimore A; Lauder SN
Curr Top Microbiol Immunol; 2022; 436():369-392. PubMed ID: 36243853
[TBL] [Abstract][Full Text] [Related]
2. PI3K Isoforms in CD8
Gaur P; Mkrtichyan M; Verma V; Jafarzadeh N; Hattar M; Gupta S; Khleif SN
Curr Top Microbiol Immunol; 2022; 436():217-234. PubMed ID: 36243846
[TBL] [Abstract][Full Text] [Related]
3. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
4. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
De Henau O; Rausch M; Winkler D; Campesato LF; Liu C; Cymerman DH; Budhu S; Ghosh A; Pink M; Tchaicha J; Douglas M; Tibbitts T; Sharma S; Proctor J; Kosmider N; White K; Stern H; Soglia J; Adams J; Palombella VJ; McGovern K; Kutok JL; Wolchok JD; Merghoub T
Nature; 2016 Nov; 539(7629):443-447. PubMed ID: 27828943
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
[TBL] [Abstract][Full Text] [Related]
6. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity.
Li Y; Shen Z; Chai Z; Zhan Y; Zhang Y; Liu Z; Liu Y; Li Z; Lin M; Zhang Z; Liu W; Guan S; Zhang J; Qian J; Ding Y; Li G; Fang Y; Deng H
Gut; 2023 Nov; 72(12):2307-2320. PubMed ID: 37507218
[TBL] [Abstract][Full Text] [Related]
7. Control of CD4
Cameron B; Zaheer SA; Dominguez-Villar M
Curr Top Microbiol Immunol; 2022; 436():197-216. PubMed ID: 36243845
[TBL] [Abstract][Full Text] [Related]
8. Class I PI3K Biology.
Aytenfisu TY; Campbell HM; Chakrabarti M; Amzel LM; Gabelli SB
Curr Top Microbiol Immunol; 2022; 436():3-49. PubMed ID: 36243838
[TBL] [Abstract][Full Text] [Related]
9. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Lim EL; Cugliandolo FM; Rosner DR; Gyori D; Roychoudhuri R; Okkenhaug K
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875319
[TBL] [Abstract][Full Text] [Related]
10. PI3K signalling in inflammation.
Hawkins PT; Stephens LR
Biochim Biophys Acta; 2015 Jun; 1851(6):882-97. PubMed ID: 25514767
[TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
Curigliano G; Shah RR
Drug Saf; 2019 Feb; 42(2):247-262. PubMed ID: 30649751
[TBL] [Abstract][Full Text] [Related]
12. Differential PI3Kδ Signaling in CD4
Ahmad S; Abu-Eid R; Shrimali R; Webb M; Verma V; Doroodchi A; Berrong Z; Samara R; Rodriguez PC; Mkrtichyan M; Khleif SN
Cancer Res; 2017 Apr; 77(8):1892-1904. PubMed ID: 28108509
[TBL] [Abstract][Full Text] [Related]
13. PI3K inhibitors are finally coming of age.
Vanhaesebroeck B; Perry MWD; Brown JR; André F; Okkenhaug K
Nat Rev Drug Discov; 2021 Oct; 20(10):741-769. PubMed ID: 34127844
[TBL] [Abstract][Full Text] [Related]
14. [PI3K isoforms PI3Kβ and PI3Kδ play different roles in KIT mutation-mediated cell transformation].
Zhang S; Zhu G; Shi J; Yang J; Jiang Z; Zhang L; Dou K; Sun J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jan; 37(1):39-46. PubMed ID: 33441227
[TBL] [Abstract][Full Text] [Related]
15. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
Gyori D; Lim EL; Grant FM; Spensberger D; Roychoudhuri R; Shuttleworth SJ; Okkenhaug K; Stephens LR; Hawkins PT
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875321
[TBL] [Abstract][Full Text] [Related]
16. Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors.
Van Dort ME; Jang Y; Bonham CA; Heist K; Palagama DSW; McDonald L; Zhang EZ; Chenevert TL; Luker GD; Ross BD
Eur J Med Chem; 2022 Feb; 229():113996. PubMed ID: 34802837
[TBL] [Abstract][Full Text] [Related]
17. PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.
Piddock RE; Loughran N; Marlein CR; Robinson SD; Edwards DR; Yu S; Pillinger GE; Zhou Z; Zaitseva L; Auger MJ; Rushworth SA; Bowles KM
Blood Cancer J; 2017 Mar; 7(3):e539. PubMed ID: 28282033
[TBL] [Abstract][Full Text] [Related]
18. PI3Kβ controls immune evasion in PTEN-deficient breast tumours.
Bergholz JS; Wang Q; Wang Q; Ramseier M; Prakadan S; Wang W; Fang R; Kabraji S; Zhou Q; Gray GK; Abell-Hart K; Xie S; Guo X; Gu H; Von T; Jiang T; Tang S; Freeman GJ; Kim HJ; Shalek AK; Roberts TM; Zhao JJ
Nature; 2023 May; 617(7959):139-146. PubMed ID: 37076617
[TBL] [Abstract][Full Text] [Related]
19. Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3Kα and PI3Kβ Activities and Is Promoted by RAS.
Molinaro A; Becattini B; Mazzoli A; Bleve A; Radici L; Maxvall I; Sopasakis VR; Molinaro A; Bäckhed F; Solinas G
Cell Metab; 2019 Jun; 29(6):1400-1409.e5. PubMed ID: 30982732
[TBL] [Abstract][Full Text] [Related]
20. Roles of TGFβ1 in the expression of phosphoinositide 3-kinase isoform genes and sensitivity and response of lung telocytes to PI3K inhibitors.
Song D; Tang L; Wang L; Huang J; Zeng T; Fang H; Wang X
Cell Biol Toxicol; 2020 Feb; 36(1):51-64. PubMed ID: 31522336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
